United Kingdom Respiratory care device
market is anticipated to register growth with an impressive CAGR in the
forecast period, 2023-2027. The market growth can be attributed to the growing
prevalence of respiratory disorders such as asthma, bronchitis, pneumonia, COPD,
and lungs cancer. Respiratory care
devices are primarily used to diagnose, treat, and monitor respiratory
diseases. According to a
research, respiratory disease is one of the biggest reasons of death in the
United Kingdom. The mortality rate due to respiratory disease in England in
2020 accounted for 89 per 100,000 for women and 130 deaths per 100,000
population for men. Besides this, the growing number of smokers and the deteriorating
quality of air due to the increasing carbon emission is giving rise to
respiratory disorders among the United Kingdom population. According to a
credible source, 13.5 percent of adults (approximately 5.5 million adults) in
the United Kingdom smoked cigarettes in Quarter 1 of 2020. As a result, cases of respiratory disorders
are increasingly rapidly which in turn is providing a thrust to the United
Kingdom respiratory care device market.
Demand for Home-Based Therapeutics Propels
the Market Growth
as the geriatric population across the
United Kingdom is rising, the cases of chronic respiratory diseases such as
COPD and asthma are also surging. as a result, the demand for homecare based
respiratory devices is also propelling. Moreover, the home care devices and
services are much more cost-effective than the hospital visits and stays. For
instance, asthmatic patients extensively utilize nebulizers in case of
shortness of breath. In addition, several key companies are focusing on
developing effective respules and therapies which can be administered through
nebulizers. They are also introducing devices which are compact and portable to
facilitate the convenience of use. Furthermore, bolstering number of product
launches and approvals and ongoing developments in the healthcare
infrastructure by the government is expected to augment the market for
respiratory care device in the United Kingdom.
Use of Combination Therapies Fuels the
Market Growth
The increasing usage of combination
therapies to treat COPS and asthma has grown rapidly. Patients are inclining
toward combination therapies due to their advantages, such as more reliability
and increased efficacy. Moreover, according to the World Health Organization
forecast, COPD will become the third primary cause of death across the world by
2025. Therefore, favorable reimbursement schemes related to therapy have been
implemented by the government, which is estimated to further propel the growth
of the United Kingdom respiratory care device market.